Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea and Thalidomide in Beta-Thalassemia
NCT05132270Phase 3Completed
- Sponsor
- National Institute of Child Health
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of thalidomide in beta thalassemia, sponsored by National Institute of Child Health. Primary endpoints: Change in transfusion requirements at 6 months, Change in Hemoglobin levels at 6 months and 2 more. Started Jan 2020; status: completed.
02
Drugs
thalidomide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05132270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05132270.